Want to see HK:0239 full AI Analyst Report?
Pak Fah Yeow International Limited (0239) AI Stock Analysis
Pak Fah Yeow International Limited
(HKEX:0239)
The overall score is driven primarily by the company’s strong financial position, combining high profitability, a very low-risk balance sheet, and solid cash generation. An attractive valuation with a low P/E and high dividend yield further supports a favorable rating. Technical indicators show a healthy uptrend with moderate bullish momentum and no clear overbought signals, reinforcing but not dominating the investment case, while the absence of recent earnings-call insights or notable corporate events leaves the assessment focused on fundamentals, price action, and valuation.
Pak Fah Yeow International Limited (0239) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 774.43M
- Dividend Yield
- 7.44%
- Average Volume (3M)
- 58.04K
- Price to Earnings (P/E)
- 7.8
- Beta (1Y)
- -0.05
- Revenue Growth
- 10.63%
- EPS Growth
- 39.44%
- Country
- Hong Kong
- Employees
- 100
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Pak Fah Yeow International Limited Business Overview & Revenue Model
Company Description
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, Sout...
How the Company Makes Money
The company primarily makes money by selling Pak Fah Yeow branded medicated oil products and related consumer healthcare items. Revenue is generated through (1) product sales into distribution networks (e.g., wholesalers, pharmacies, retailers, and o...
Pak Fah Yeow International Limited Financial Statement Overview
Summary
Strong profitability, conservative leverage close to zero, and robust cash generation support a high score, though cyclical revenue, margin swings, and volatile free cash flow prevent a top-tier rating.
Income Statement
84Very PositiveBalance Sheet
90Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 220.18M | 213.88M | 236.91M | 259.31M | 147.20M | 139.82M |
| Gross Profit | 140.54M | 133.14M | 203.20M | 167.59M | 74.06M | 68.71M |
| EBITDA | 133.21M | 115.35M | 105.73M | 136.81M | 45.90M | 54.67M |
| Net Income | 98.95M | 91.35M | 78.63M | 105.04M | 29.95M | 38.19M |
Balance Sheet | ||||||
| Total Assets | 878.30M | 828.37M | 843.35M | 907.47M | 823.14M | 837.75M |
| Cash, Cash Equivalents and Short-Term Investments | 400.27M | 344.54M | 290.02M | 277.61M | 180.34M | 178.28M |
| Total Debt | 6.95M | 6.87M | 4.20M | 4.74M | 5.50M | 16.21M |
| Total Liabilities | 144.25M | 105.63M | 111.45M | 142.28M | 115.91M | 130.03M |
| Stockholders Equity | 734.04M | 722.75M | 731.91M | 765.18M | 707.23M | 707.72M |
Cash Flow | ||||||
| Free Cash Flow | 91.38M | 112.33M | 78.02M | 144.84M | 39.76M | 69.54M |
| Operating Cash Flow | 97.80M | 112.77M | 78.96M | 147.90M | 39.92M | 70.36M |
| Investing Cash Flow | -5.78M | -63.29M | -3.19M | 16.65M | -6.67M | -565.00K |
| Financing Cash Flow | -57.60M | -57.67M | -67.54M | -48.96M | -33.91M | -22.41M |
Pak Fah Yeow International Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0239, the sentiment is Positive. The current price of 2.48 is above the 20-day moving average (MA) of 2.42, above the 50-day MA of 2.42, and above the 200-day MA of 2.28, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 68.99 is Neutral, neither overbought nor oversold. The STOCH value of 86.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0239.
Pak Fah Yeow International Limited Peers Comparison
Overall Rating
- HK:023986Outperform
HK:216173Outperform
HK:263370Outperform
HK:234859Neutral
HK:089758.6Neutral
HK:057052.75Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 86Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:2161 | 73Outperform | HKD 1.36B | 6.64 | 18.70% | 10.30% | 6.69% | 2.45% |
| HK:2633 | 70Outperform | HKD 1.78B | 6.19 | 13.26% | 9.67% | -0.47% | -0.40% |
| HK:2348 | 59Neutral | HKD 1.39B | 5.11 | 6.78% | 6.85% | 6.55% | 36.62% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:0570 | 53Neutral | HKD 5.89B | -4.80 | -4.98% | 0.30% | -15.80% | -298.94% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% | |
| HK:0570 | China Traditional Chinese Medicine Holdings Co | 1.17 | -1.16 | -49.79% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:2161 | JBM (Healthcare) Ltd. | 1.66 | -1.11 | -40.09% | |
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.92 | -0.20 | -17.86% | |
| HK:2633 | Jacobson Pharma Corporation Limited | 0.94 | -0.42 | -30.74% |
Pak Fah Yeow International Limited Corporate Events
Pak Fah Yeow boosts interim profit and dividends on healthcare growth
Pak Fah Yeow International Limited reported interim results for the six months ended 30 June 2026 showing a 6.7% year-on-year increase in revenue to HK$101.0 million and a 3.7% rise in underlying recurring profit, driven mainly by stronger sales from...
Pak Fah Yeow Declares Interim and Special Dividends for 2026
Pak Fah Yeow International Limited, incorporated in Bermuda and listed on the Hong Kong Stock Exchange, operates in the consumer healthcare sector with a focus on medicated oils and related wellness products. The board is led by Chairman Gan Wee Sean...
Pak Fah Yeow Declares Interim Dividend for First Half of 2026
Pak Fah Yeow International Limited, a Hong Kong‑listed healthcare and consumer products company, derives its business from the regional market, with shares quoted on the Main Board under stock code 00239. The board comprises a mix of executive,...
Pak Fah Yeow Declares Special Interim Dividend for First Half of 2026
Pak Fah Yeow International Limited, a Hong Kong-listed consumer healthcare company known for its medicated oils and topical remedies, generates steady cash flow from its established brands in regional markets. Its defensively positioned business and...
Pak Fah Yeow Sets August Board Meeting to Review Interim Results and Dividend
Pak Fah Yeow International Limited has scheduled a board meeting for 20 August 2026 to review and approve the interim results of the company and its subsidiaries for the six months ended 30 June 2026. The board will also consider the declaration of a...
Pak Fah Yeow flags higher interim profit on revenue growth and lower property losses
Pak Fah Yeow International has issued a positive profit alert, indicating that consolidated net profit attributable to shareholders for the six months ended 30 June 2026 is expected to rise to about HK$47.4 million, up from HK$39.7 million a year ear...
Pak Fah Yeow Owner Restructures Hexagan Stake in Family Succession Move
Pak Fah Yeow International Limited has announced a change in the shareholding structure of its substantial shareholder Hexagan Enterprises Limited as part of a family succession plan. The move affects ownership of Hexagan itself but leaves the compan...
Pak Fah Yeow Wins Strong Shareholder Backing for Dividends, Mandates and Bye-law Changes
Shareholders of Pak Fah Yeow International Limited overwhelmingly approved all resolutions at the 2 June 2026 annual general meeting, including the 2025 financial statements and the payment of both a final dividend of HK3.8 cents per share and a spec...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026